Few studies have compared head to head the 2nd generation drug eluting stents. This study randomized 1:1 3671 patients to receive a biolimus eluting stent with biodegradable polymer (1880 patients) versus zotarolimus-eluting stent with biocompatible polymer (1791 patients). No significant differences were observed between the two groups in terms of clinical or angiographic features. Approximately 50% in both groups were experiencing an acute coronary syndrome. At follow-up there were no significant differences in major cardiac events (5.3% to 5.1% for zotarolimus versus biolimus).
Conclusion: Biolimus eluting stent and zotarolimus eluting stent showed similar safety and efficacy.
Bent Raungaard
2013-10-29
